Lupin Gives Direction On Pegfilgrastim And Ranibizumab

Neulasta Biosimilar Previously Slated For FY2021

 
• By Dean Rudge
  
Bulb
Lupin has ambitions to grow its biosimilars portfolio in the next two years • Source: Shutterstock

More from Biosimilars

More from Products